Last updated: 11/04/2018 10:26:50

Exploratory study to evaluate the efficacy of an occlusion based dentifrice in relief of dentinal hypersensitivity

GSK study ID
RH01591
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Proof of Concept Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in the Relief of Dentinal Hypersensitivity
Trial description: The purpose of this exploratory study is to compare the treatment effect on dentinal hypersensitivity of a tubule occluding dentifrice as measured by Schiff and Tactile sensitivity. This proof of concept study will compare the test dentifrice with three other treatment groups.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Single (Investigator)
Allocation:
Randomized
Primary outcomes:

Mean change from baseline in Schiff sensitivity score at Week 4

Timeframe: Baseline and 4 weeks post administration of study treatment

Mean Change from baseline in Schiff Sensitivity Score at Week 8

Timeframe: Baseline and 8 weeks post administration of study treatment

Median change from baseline in Tactile sensitivity at Week 4

Timeframe: Baseline and 4 weeks post administration of study treatment

Median change from baseline in Tactile sensitivity at Week 8

Timeframe: Baseline and 8 weeks post administration of study treatment

Mean change from baseline in Visual rating scale score at Week 4

Timeframe: Baseline and 4 weeks post administration of study treatment

Mean change from baseline in Visual rating scale score at Week 8

Timeframe: Baseline and 8 weeks post administration of study treatment

Secondary outcomes:

Mean change from baseline in Dentine Hypersensitivity Experience Questionnaire total score at Week 4

Timeframe: Baseline and 4 weeks post administration of study treatment

Mean change from baseline in Dentine Hypersensitivity Experience Questionnaire (DHEQ) total score at Week 8

Timeframe: Baseline and 8 weeks post administration of study treatment

Interventions:
  • Drug: 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
  • Drug: 0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
  • Drug: Sodium monofluorophosphate dentifrice
  • Drug: Sodium Fluoride dentifrice
  • Enrollment:
    140
    Primary completion date:
    2013-31-05
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Dentinal Hypersensitivity
    Product
    Calcium sodium phosphosilicate/ sodium monofluorophosphate
    Collaborators
    Not applicable
    Study date(s)
    January 2013 to May 2013
    Type
    Interventional
    Phase
    2

    Participation criteria

    Sex
    Female & Male
    Age
    18 - 55 years
    Accepts healthy volunteers
    Yes
    • Participants between 18 and 55 years of age, in good general health, with pre-existing self-reported and clinically diagnosed tooth sensitivity are required for entry into the study.
    • Participants will be required to have at least four teeth with facial/cervical erosion, abrasion and/or gingival recession which respond to qualifying evaporative (air) assessment at the Screening visit and have at least two teeth (incisors, canines or pre-molars) demonstrating signs of sensitivity, measured by qualifying tactile threshold (Yeaple ≤ 20 gram (g)) and evaporative (air) (Schiff Sensitivity Score ≥ 2) assessments at the Baseline visit.
    • Specific Dentition Exclusions for Test teeth
    • a) Tooth with evidence of current or recent caries, or reported treatment of decay in 12 months of Screening.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    Salus Research, Inc.
    Fort Wayne, IN, United States, 46825
    Status
    Study Complete

    Study documents

    Scientific result summary
    Available language(s): English

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Results posted on ClinicalTrials.gov

    Recruitment status
    Study complete
    Actual primary completion date
    2013-31-05
    Actual study completion date
    2013-31-05

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website